APPROACHES TO SELECTION OF ANTIHYPERTENSION DRUG WITHIN APPLIED LOWER TARGET BLOOD PRESSURE LEVELS
https://doi.org/10.15829/1560-4071-2017-12-90-96
Abstract
In the article, contemporary tendencies are discussed, of the shifts in targeted and threshold systemic blood pressure levels (BP), as the specifics of antihypertension therapy, which are induced by such tendencies. The issue discussed, on the risk increase for acute kidney injury while achieving target BP and possible approaches to its solution. Evidence data is shown on the angiotensin II receptor blockers influence on kidney function. The data presented, that makes it to suppose special role of irbesartan in prevention of kidney dysfunction prevention.
About the Authors
S. R. Gilyarevsky
Russian Medical Academy of Continuous Professional Education of the Ministry of Health
Russian Federation
Russian Federation
Moscow
М. V. Golshmid
Russian Medical Academy of Continuous Professional Education of the Ministry of Health
Russian Federation
Russian Federation
Moscow
I. М. Kuzmina
N. V. Sklifosovsky SRI of Emergency Care
Russian Federation
Russian Federation
Moscow
References
1. Whelton PK, Carey RM, Aronow WS, et al . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13. DOI: 10.1161/HYP.0000000000000065. [Epub ahead of print]
2. Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373: 2103-16. DOI: 10.1056/NEJMoa1511939.
3. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-83. DOI:10.1001/archinte.1993.00410020010002.
4. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-67. DOI: 10.1016/S0140-6736(15)01225-8.
5. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996; 312: 71-2. DOI: 10.1136/bmj.312.7023.71.
6. Simpkin AL, Schwartzstein RM. Tolerating Uncertainty — The Next Medical Revolution? N Engl J Med 2016; 375: 1713-5. DOI: 10.1056/NEJMp1606402.
7. Bangalore S, Fakheri R, Toklu B, et al. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clin Proc 2016; 91: 51-60. DOI: 10.1016/j.mayocp.2015.10.019.
8. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8. DOI: 10.1056/NEJMoa011489.
9. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
10. ONTARGET Study Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59. DOI: 10.1056/NEJMoa0801317.
11. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174-83. DOI: 10.1016/S0140-6736(08)61242-8.
12. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-17. DOI: 10.1056/NEJMoa1007994.
13. Frieden TR. Evidence for Health Decision Making — Beyond Randomized, Controlled Trials. N Engl J Med 2017; 377: 465-75. DOI: 10.1056/NEJMra1614394.
14. Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther 2011; 33: 1190-203. DOI: 10.1016/j.clinthera.2011.08.008.
15. Petrella RJ, Charki M. Ananalysis of the antihypertensive effectiveness of combination therapies containing ARBs versus ACE inhibitors. Value in Health 2009; Volume 12, Issue 7, Page A315. DOI: 10.1016/S1098-3015(10)74548-4.
16. Sharplin P, Chamberlain G, Beckham C, Wisniacki N. Antihypertensive effect of angiotensin receptor blockers vs. other classes of antihypertensives in UK primary care. Presented at American College of Cardiology; March 29–April 1, 2008; Chicago, IL.
17. Sharplin P, Beckham C, Televantou F, Chamberlain G. An analysis of the antihypertensive effectiveness of ARBs vs. ACE inhibitors. Value in Health 2008; Volume 11, Issue 6, Page A384. DOI: 10.1016/S1098-3015(10)66312-7.
18. Bobrie G., Delonca J, Moulin C, et al. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens 2005; 18: 1482-8. DOI: 10.1016/j.amjhyper.2005.06.009.
19. Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mildto-moderate hypertension. J Int Med Res 2005; 33: 620-31. DOI: 10.1177/147323000503300603.
20. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT–BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. DOI: 10.1016/S0140-6736(05)67185-1.
21. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28. DOI: 10.1056/NEJMoa0806182.
22. Motozato K, Miura S, Shiga Y, et al. Efficacy and safety of two single-pill fixeddose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study). Clin Exp Hypertens 2016; 38: 45-50. DOI: 10.3109/10641963.2015.1060982.
Review
For citations:
Gilyarevsky S.R., Golshmid М.V., Kuzmina I.М. APPROACHES TO SELECTION OF ANTIHYPERTENSION DRUG WITHIN APPLIED LOWER TARGET BLOOD PRESSURE LEVELS. Russian Journal of Cardiology. 2017;(12):90-96. (In Russ.) https://doi.org/10.15829/1560-4071-2017-12-90-96
Views:
812
Email this article 